产品
编 号：F215331
分子式：C17H20ClFN4O2S2
分子量：430.95
分子式：C17H20ClFN4O2S2
分子量：430.95
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1788872-06-9
产品详情
生物活性：
Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration.
体内研究：
Nav1.7-IN-3 (compound 5) shows excellent potency, selectivity, behavioral efficacy in a rodent pain model (30 mg/kg, oral, 35 minutes), and efficacy in a mouse itch model (30 mg/kg, oral, 30 minutes).Animal Model:C57BL/6 male mice (n=8/group, 25-30g)
Dosage:1, 3, and 10 mg/kg
Administration:Oral (0-35 mintues)
Result:Nav1.7-IN-3 demonstrates statistically significant, dose-dependent reversal of these effects in the acute phase of the experiment (0-5 min period post formalin injection) and the tonic phase of the experiment (20-35 min period post formalin injection) with full reversal of formalin effects in the tonic phase
Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration.
体内研究：
Nav1.7-IN-3 (compound 5) shows excellent potency, selectivity, behavioral efficacy in a rodent pain model (30 mg/kg, oral, 35 minutes), and efficacy in a mouse itch model (30 mg/kg, oral, 30 minutes).Animal Model:C57BL/6 male mice (n=8/group, 25-30g)
Dosage:1, 3, and 10 mg/kg
Administration:Oral (0-35 mintues)
Result:Nav1.7-IN-3 demonstrates statistically significant, dose-dependent reversal of these effects in the acute phase of the experiment (0-5 min period post formalin injection) and the tonic phase of the experiment (20-35 min period post formalin injection) with full reversal of formalin effects in the tonic phase
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备